CLYM
Price
$1.51
Change
+$0.05 (+3.42%)
Updated
Jul 18 closing price
Capitalization
102.04M
30 days until earnings call
RXRX
Price
$5.84
Change
+$0.32 (+5.80%)
Updated
Jul 18 closing price
Capitalization
2.53B
23 days until earnings call
Interact to see
Advertisement

CLYM vs RXRX

Header iconCLYM vs RXRX Comparison
Open Charts CLYM vs RXRXBanner chart's image
Climb Bio
Price$1.51
Change+$0.05 (+3.42%)
Volume$159.19K
Capitalization102.04M
Recursion Pharmaceuticals
Price$5.84
Change+$0.32 (+5.80%)
Volume$53.04M
Capitalization2.53B
CLYM vs RXRX Comparison Chart in %
Loading...
CLYM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLYM vs. RXRX commentary
Jul 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLYM is a Hold and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 20, 2025
Stock price -- (CLYM: $1.51 vs. RXRX: $5.84)
Brand notoriety: CLYM and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLYM: 58% vs. RXRX: 191%
Market capitalization -- CLYM: $102.04M vs. RXRX: $2.53B
CLYM [@Biotechnology] is valued at $102.04M. RXRX’s [@Biotechnology] market capitalization is $2.53B. The market cap for tickers in the [@Biotechnology] industry ranges from $293.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLYM’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • CLYM’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both CLYM and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLYM’s TA Score shows that 6 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • CLYM’s TA Score: 6 bullish, 4 bearish.
  • RXRX’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than CLYM.

Price Growth

CLYM (@Biotechnology) experienced а +10.22% price change this week, while RXRX (@Biotechnology) price change was +10.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

CLYM is expected to report earnings on Aug 19, 2025.

RXRX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.53B) has a higher market cap than CLYM($102M). RXRX YTD gains are higher at: -13.609 vs. CLYM (-16.111). CLYM has higher annual earnings (EBITDA): -50.37M vs. RXRX (-524.77M). RXRX has more cash in the bank: 500M vs. CLYM (98.1M). CLYM has less debt than RXRX: CLYM (474K) vs RXRX (92.9M). RXRX has higher revenues than CLYM: RXRX (59.8M) vs CLYM (0).
CLYMRXRXCLYM / RXRX
Capitalization102M2.53B4%
EBITDA-50.37M-524.77M10%
Gain YTD-16.111-13.609118%
P/E RatioN/AN/A-
Revenue059.8M-
Total Cash98.1M500M20%
Total Debt474K92.9M1%
TECHNICAL ANALYSIS
Technical Analysis
CLYMRXRX
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 24 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
66%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CLYM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGRBX43.920.14
+0.32%
MFS International Growth B
JNGSX12.000.02
+0.17%
Janus Henderson Global Real Estate D
TQVAX18.180.02
+0.11%
T. Rowe Price Integrated US LCV Eq Adv
IVOYX19.44N/A
N/A
Macquarie Mid Cap Income Opps Y
TEQIX15.16-0.04
-0.26%
Franklin Mutual Quest A

CLYM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLYM has been loosely correlated with ABOS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CLYM jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLYM
1D Price
Change %
CLYM100%
+3.42%
ABOS - CLYM
45%
Loosely correlated
+1.35%
RXRX - CLYM
39%
Loosely correlated
+5.80%
PDSB - CLYM
39%
Loosely correlated
-4.17%
CLDX - CLYM
39%
Loosely correlated
-2.44%
CRSP - CLYM
39%
Loosely correlated
+18.22%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+5.80%
CRSP - RXRX
70%
Closely correlated
+18.22%
ABSI - RXRX
64%
Loosely correlated
+8.33%
BEAM - RXRX
64%
Loosely correlated
+1.47%
ABCL - RXRX
58%
Loosely correlated
+14.62%
NTLA - RXRX
57%
Loosely correlated
+1.94%
More